Early treatment with combination of SS31 and entresto effectively preserved the heart function in doxorubicin-induced dilated cardiomyopathic rat.

Yeh JN, Sung PH, Chiang JY, Sheu JJ, Huang CR, Chu YC, Chua S, Yip HK

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie10 Aug 2021Cited by 8 (Europe PMC)

PMID34426177DOI10.1016/j.biopha.2021.111886PepBankPUB-34426177

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

2 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced dilated cardiomyopathy, LVEF did not differ between SS31 alone and entresto alone.
In plain wordsIn rats with heart damage, SS31 alone and entresto alone gave similar heart pumping.
Peptide
Elamipretide (SS-31)
Outcome
No significant changeLeft-ventricular ejection fraction at day 60
Study
ratn: not reported in source
Doxorubicin-induced dilated cardiomyopathy
Comparator
Entresto alone
Outcome group
Heart function · Cardiovascular
Studied dose
0.7 mg/kg/day · intraperitoneal · day 14 to day 60 after DCM inductionAs given in this study (rat).
Source sentences
Summary
it showed no difference between groups 3/4.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult-male SD rats (n = 40) were equally categorized into groups 1 (sham-control), 2 (DCM), 3 (DCM + SS31/0.7 mg/kg/day/IP, since day-14 after DCM induction to day-60), 4 [DCM + En (30 mg/kg/day/orally since day-14 after DCM induction to day-60)] and 5 (DCM + combined SS31-En), and animals were euthanized by day 60.
Report a problemFND-3442617702
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced dilated cardiomyopathy, combined SS31 plus entresto gave a significantly higher LVEF than entresto alone at day 60.
In plain wordsIn rats with heart damage, adding SS31 to entresto gave better heart pumping than entresto alone.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseLeft-ventricular ejection fraction at day 60
Study
ratn: not reported in source
Doxorubicin-induced dilated cardiomyopathy
Comparator
Entresto alone
Outcome group
Heart function · Cardiovascular
Studied dose
0.7 mg/kg/day · intraperitoneal · day 14 to day 60 after DCM inductionAs given in this study (rat).
Source sentences
Summary
By day 60, left-ventricular ejection-fraction (LVEF) was highest in group 1, lowest in group 2 and significantly higher in group 5 than in groups 3 and 4 (all p < 0.0001), but it showed no difference between groups 3/4.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult-male SD rats (n = 40) were equally categorized into groups 1 (sham-control), 2 (DCM), 3 (DCM + SS31/0.7 mg/kg/day/IP, since day-14 after DCM induction to day-60), 4 [DCM + En (30 mg/kg/day/orally since day-14 after DCM induction to day-60)] and 5 (DCM + combined SS31-En), and animals were euthanized by day 60.
Report a problemFND-3442617709

Studies that did not test the peptide alone7

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced dilated cardiomyopathy, combined SS31 plus entresto gave a higher LVEF than SS31 alone or entresto alone at day 60.
In plain wordsIn rats with heart damage, the SS31 plus entresto combination gave better heart pumping than either drug alone.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseLeft-ventricular ejection fraction at day 60
Study
ratn = 40
Doxorubicin-induced dilated cardiomyopathy
Comparator
SS31 alone and entresto alone (groups 3 and 4)
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
By day 60, left-ventricular ejection-fraction (LVEF) was highest in group 1, lowest in group 2 and significantly higher in group 5 than in groups 3 and 4 (all p < 0.0001), but it showed no difference between groups 3/4.
1 context sentence(design, population, supporting numbers)
Summary · context
Adult-male SD rats (n = 40) were equally categorized into groups 1 (sham-control), 2 (DCM), 3 (DCM + SS31/0.7 mg/kg/day/IP, since day-14 after DCM induction to day-60), 4 [DCM + En (30 mg/kg/day/orally since day-14 after DCM induction to day-60)] and 5 (DCM + combined SS31-En), and animals were euthanized by day 60.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3442617701
04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced dilated cardiomyopathy, fibrosis area and cardiomyocyte size followed the opposite pattern of LVEF across the five groups, including the SS31 plus entresto group.
In plain wordsIn rats with heart damage, scarring and heart cell size followed the reverse pattern of heart pumping across groups, including the SS31 plus entresto group.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseFibrosis area and cardiomyocyte size
Study
ratn = 40
Doxorubicin-induced dilated cardiomyopathy
Comparator
SS31 alone and entresto alone (groups 3 and 4)
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
The microscopic study showed that the fibrosis area/cardiomyocyte size
2 context sentences(design, population, supporting numbers)
Summary · context
exhibited an opposite pattern of LVEF among the five groups (all p < 0.0001).
Summary · context
Adult-male SD rats (n = 40) were equally categorized into groups 1 (sham-control), 2 (DCM), 3 (DCM + SS31/0.7 mg/kg/day/IP, since day-14 after DCM induction to day-60), 4 [DCM + En (30 mg/kg/day/orally since day-14 after DCM induction to day-60)] and 5 (DCM + combined SS31-En), and animals were euthanized by day 60.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3442617703
05AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced dilated cardiomyopathy, DNA-damage and inflammatory markers followed the opposite pattern of LVEF across the five groups, including the SS31 plus entresto group.
In plain wordsIn rats with heart damage, DNA damage and inflammation markers followed the reverse pattern of heart pumping across groups, including the SS31 plus entresto group.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseDNA-damage and inflammatory markers (microscopy)
Study
ratn = 40
Doxorubicin-induced dilated cardiomyopathy
Comparator
SS31 alone and entresto alone (groups 3 and 4)
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
DNA-damaged (γ-H2AX+)/inflammatory (CD14+//CD68+) markers
2 context sentences(design, population, supporting numbers)
Summary · context
exhibited an opposite pattern of LVEF among the five groups (all p < 0.0001).
Summary · context
Adult-male SD rats (n = 40) were equally categorized into groups 1 (sham-control), 2 (DCM), 3 (DCM + SS31/0.7 mg/kg/day/IP, since day-14 after DCM induction to day-60), 4 [DCM + En (30 mg/kg/day/orally since day-14 after DCM induction to day-60)] and 5 (DCM + combined SS31-En), and animals were euthanized by day 60.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3442617704
06AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced dilated cardiomyopathy, inflammatory and apoptotic cells by flow analysis followed the opposite pattern of LVEF across the five groups, including the SS31 plus entresto group.
In plain wordsIn rats with heart damage, inflammatory and dying cells followed the reverse pattern of heart pumping across groups, including the SS31 plus entresto group.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseInflammatory and apoptotic cells (flow analysis)
Study
ratn = 40
Doxorubicin-induced dilated cardiomyopathy
Comparator
SS31 alone and entresto alone (groups 3 and 4)
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
and flow analysis of inflammatory (Ly6G+/MPO+/CD11^b/c+) and early/late apoptosis (AN-V⁺/PI^-//AN-V⁺/PI⁺) cells exhibited an opposite pattern of LVEF among the five groups (all p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Adult-male SD rats (n = 40) were equally categorized into groups 1 (sham-control), 2 (DCM), 3 (DCM + SS31/0.7 mg/kg/day/IP, since day-14 after DCM induction to day-60), 4 [DCM + En (30 mg/kg/day/orally since day-14 after DCM induction to day-60)] and 5 (DCM + combined SS31-En), and animals were euthanized by day 60.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3442617705
07AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced dilated cardiomyopathy, expression of upstream and downstream inflammatory signaling proteins followed the opposite pattern of LVEF across the five groups, including the SS31 plus entresto group.
In plain wordsIn rats with heart damage, inflammation signaling proteins followed the reverse pattern of heart pumping across groups, including the SS31 plus entresto group.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseInflammatory signaling protein expression
Study
ratn = 40
Doxorubicin-induced dilated cardiomyopathy
Comparator
SS31 alone and entresto alone (groups 3 and 4)
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
The protein expressions of inflammatory upstream (TLR2/TLR4/MyD88/Mal/ TRAF6/IKK-α/IKK-ß) and downstream (p-NF-κb/TNF-α/IL-1ß/MMP-9)
2 context sentences(design, population, supporting numbers)
Summary · context
also exhibited an opposite pattern of LVEF among the five groups (all p < 0.0001).
Summary · context
Adult-male SD rats (n = 40) were equally categorized into groups 1 (sham-control), 2 (DCM), 3 (DCM + SS31/0.7 mg/kg/day/IP, since day-14 after DCM induction to day-60), 4 [DCM + En (30 mg/kg/day/orally since day-14 after DCM induction to day-60)] and 5 (DCM + combined SS31-En), and animals were euthanized by day 60.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3442617706
08AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced dilated cardiomyopathy, oxidative-stress and mitochondrial-damage proteins followed the opposite pattern of LVEF across the five groups, including the SS31 plus entresto group.
In plain wordsIn rats with heart damage, oxidative stress and mitochondrial damage proteins followed the reverse pattern of heart pumping across groups, including SS31 plus entresto.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseOxidative-stress and mitochondrial-damage protein expression
Study
ratn = 40
Doxorubicin-induced dilated cardiomyopathy
Comparator
SS31 alone and entresto alone (groups 3 and 4)
Outcome group
Mitochondrial function · Cardiovascular
Source sentences
Summary
oxidative-stress/mitochondrial-damaged (NOX-1/NOX-2/cytosolic cytochrome-C/cyclophilin-D/DRP1)
2 context sentences(design, population, supporting numbers)
Summary · context
also exhibited an opposite pattern of LVEF among the five groups (all p < 0.0001).
Summary · context
Adult-male SD rats (n = 40) were equally categorized into groups 1 (sham-control), 2 (DCM), 3 (DCM + SS31/0.7 mg/kg/day/IP, since day-14 after DCM induction to day-60), 4 [DCM + En (30 mg/kg/day/orally since day-14 after DCM induction to day-60)] and 5 (DCM + combined SS31-En), and animals were euthanized by day 60.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3442617707
09AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In rats with doxorubicin-induced dilated cardiomyopathy, autophagic and apoptotic signaling proteins followed the opposite pattern of LVEF across the five groups, including the SS31 plus entresto group.
In plain wordsIn rats with heart damage, cell-death and recycling proteins followed the reverse pattern of heart pumping across groups, including the SS31 plus entresto group.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseAutophagic and apoptotic signaling protein expression
Study
ratn = 40
Doxorubicin-induced dilated cardiomyopathy
Comparator
SS31 alone and entresto alone (groups 3 and 4)
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
autophagic/apoptotic (ratio of LC3B-II/LC3B-I and mitochondrial-Bax/caspase3/9)
2 context sentences(design, population, supporting numbers)
Summary · context
also exhibited an opposite pattern of LVEF among the five groups (all p < 0.0001).
Summary · context
Adult-male SD rats (n = 40) were equally categorized into groups 1 (sham-control), 2 (DCM), 3 (DCM + SS31/0.7 mg/kg/day/IP, since day-14 after DCM induction to day-60), 4 [DCM + En (30 mg/kg/day/orally since day-14 after DCM induction to day-60)] and 5 (DCM + combined SS31-En), and animals were euthanized by day 60.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-3442617708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.